Specific and Sensitive Hydrolysis Probe-Based Real-Time PCR Detection of Epidermal Growth Factor Receptor Variant III in Oral Squamous Cell Carcinoma by McIntyre, John B. et al.
Specific and Sensitive Hydrolysis Probe-Based Real-Time
PCR Detection of Epidermal Growth Factor Receptor
Variant III in Oral Squamous Cell Carcinoma
John B. McIntyre
1., Pinaki Bose
2., Alexander C. Klimowicz
2, Nigel T. Brockton
3, Stephanie Petrillo
2,
Wayne Matthews
4, Jay Easaw
5, Anthony Magliocco
2, Joseph C. Dort
4*
1Department of Pathology and Laboratory Medicine, Tom Baker Cancer Centre, University of Calgary, Calgary, Canada, 2Department of Oncology, University of Calgary,
Calgary, Canada, 3Department of Population Health Research, Alberta Health Services - Cancer Care, Calgary, Canada, 4Department of Surgery (Division of
Otolaryngology-Head and Neck Surgery), University of Calgary, Calgary, Canada, 5Division of Neurosurgery, Department of Clinical Neurosciences, University of Calgary,
Calgary, Canada
Abstract
Background: The tumor-specific EGFR deletion mutant, EGFRvIII, is characterised by ligand-independent constitutive
signalling. Tumors expressing EGFRvIII are resistant to current EGFR-targeted therapy. The frequency of EGFRvIII in head and
neck squamous cell carcinoma (HNSCC) is disputed and may vary by specific sub-site. The purpose of this study was to
measure the occurrence of EGFRvIII mutations in a specific HNSCC subsite, oral squamous cell carcinoma (OSCC), using a
novel real-time PCR assay.
Methodology: Pre-treatment Formalin Fixed Paraffin Embedded (FFPE) cancer specimens from 50 OSCC patients were
evaluated for the presence of EGFRvIII using a novel hydrolysis probe-based real-time PCR assay. EGFR protein expression in
tumor samples was quantified using fluorescent immunohistochemistry (IHC) and AQUAH technology.
Principal findings: We detected EGFRvIII in a single OSCC patient in our cohort (2%). We confirmed the validity of our
detection technique in an independent cohort of glioblastoma patients. We also compared the sensitivity and specificity of
our novel real-time EGFRvIII detection assay to conventional RT-PCR and direct sequencing. Our assay can specifically detect
EGFRvIII and can discriminate against wild-type EGFR in FFPE tumor samples. AQUAnalysisH revealed that the presence of
EGFRvIII transcript is associated with very high EGFR protein expression (98
th percentile). Contrary to previous reports, only
44% of OSCC over-expressed EGFR in our study.
Conclusion and Significance: Our results suggest that the EGFRvIII mutation is rare in OSCC and corroborate previous
reports of EGFRvIII expression only in tumors with extreme over-expression of EGFR. We conclude that EGFRvIII-specific
therapies may not be ideally suited as first-line treatment in OSCC. Furthermore, highly specific and sensitive methods, such
as the real-time RT-PCR assay and AQUAnalysisH described here, will provide accurate assessment of EGFR mutation
frequency and EGFR expression, and will facilitate the selection of optimal tailored therapies for OSCC patients.
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Introduction
The discovery of oncogenic mutations in key genes regulating
growth and proliferation has enhanced our understanding of the
molecular pathology of cancer [1]. Many of these mutations are
shared by tumors arising in distinct tissue types and at diverse
anatomical locations, thereby emphasizing their vital importance
in carcinogenesis. The epidermal growth factor receptor (EGFR)
signalling pathway is frequently dysregulated in several cancer
types. EGFR is a membrane-spanning glycoprotein consisting of
an extracellular ligand-binding domain, a transmembrane do-
main, and an intracellular tyrosine kinase domain. EGFR
mediates a variety of responses including growth, proliferation,
angiogenesis and metastasis [2]. On ligand binding, EGFR can
activate two major signalling pathways: Ras/MAPK and PI3K/
AKT/mTOR pathways (Reviewed in [3,4]). EGFR is ubiquitous-
ly expressed in normal epithelial tissue but is over-expressed in
several cancers including lung, glioblastoma, prostrate, breast,
colon, ovary and head and neck. Mutations in the EGFR gene
have also been described in a variety of cancers.
Our study focuses on the most common and well-characterized
EGFR mutant, EGFR class III variant (EGFRvIII) [5]. EGFRvIII is
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31723a cancer-specific deletion of exons 2 to 7 (801 bp) that results in a
truncated extracellular domain of EGFR [6]. The corresponding
deletion of amino acids 30–297 within the extracellular ligand-
binding domain, results in a ligand-independent form of EGFR
with constitutive tyrosine kinase activity [7], leading to increased
cell proliferation and inhibition of apoptosis [7]. EGFRvIII
expression is frequently associated with amplification and over-
expression of wild-type EGFR [8,9] and EGFRvIII-expressing
tumors are more resistant to radiotherapy and chemotherapy
[10,11].
The EGFRvIII mutant was first detected in glioblastomas
[12,13,14] and approximately 30% of glioblastomas express
EGFRvIII [15]. EGFRvIII has been reported in lung squamous
cell carcinomas but not in adenocarcinomas [16,17]. EGFRvIII has
also been reported in breast cancer and ovarian cancer [5]. In
prostrate tumors, EGFRvIII expression increases progressively
during the transition from pre-malignant prostate lesions to the
malignant phenotype [18].
Previous reports suggest that EGFR is over-expressed in ,90%
of head and neck squamous cell carcinoma (HNSCC) [19,20,21]
and EGFR over-expression has been linked to the presence of
EGFRvIII at other cancer sites [8,9]. Therefore, recent studies
have examined the role of EGFRvIII in HNSCC etiology
[21,22,23]. However, the frequency of EGFRvIII in head and
neck cancer is disputed [24]. Two studies have reported the
presence of EGFRvIII in 42% of HNSCC patients [22,23] but
another group did not detect any EGFRvIII in HNSCC patients
[21]. One study, specifically in laryngeal carcinoma patients,
reported the presence of EGFRvIII in ,15% of tumor samples
[25].
The level of EGFR protein expression in HNSCC can vary
according to the specific subsite; for instance, carcinomas of the
pharynx and oral cavity tend to have higher EGFR expression
than those of the larynx [26]. Therefore, the frequency of
EGFRvIII expression may also differ in distinct HNSCC subsites.
Despite the lack of consensus on the frequency of EGFRvIII in
HNSCC [24], only one study has discussed the frequency of
EGFRvIII in specific HNSCC subsites which include malignancies
of the oral cavity, pharynx and larynx.
Oral squamous cell carcinoma (OSCC) accounts for approxi-
mately 30% of all HNSCCs. The 5-year survival rate for OSCC is
approximately 50% and has changed little in the last few decades.
This failure of conventional therapies supports the use of novel
therapeutic strategies in OSCC. Therapeutic agents that target
specific abnormalities in HNSCC have been employed successfully
in recent years [27]. The reduced toxicity profile of these agents,
compared to conventional chemotherapy and radiotherapy
regimens, spares the surrounding non-cancer tissue from the
deleterious effects of such therapy. Monoclonal antibodies and
small molecule tyrosine kinase inhibitors have been developed to
target EGFR in diverse tumor types. The most commonly used
anti-EGFR therapy is Cetuximab (ImClone LLC). However,
Cetuximab binds in the ligand-binding domain that is deleted in
the EGFRvIII mutant form, rendering EGFRvIII-positive tumors
refractory to Cetuximab treatment [22]. Consequently, the
effective targeting of these novel therapies depends on the sensitive
and reliable detection of these specific abnormalities to identify
patients who are candidates for these agents.
The use of immunohistochemistry to detect EGFRvIII protein
expression in clinical samples is restricted by existing patents [28].
Also, the limited availability of frozen tissue poses a significant
challenge to the use of conventional reverse transcriptase-PCR
(RT-PCR) and Southern blot assays for the detection of EGFRvIII
since they require high nucleic acid integrity. Thus, robust and
sensitive methods for detecting EGFRvIII in FFPE samples are
required. Several real-time PCR assays have been developed for
the detection of EGFRvIII in FFPE tumor samples [23,28]. In the
present study, we developed a highly sensitive and specific
hydrolysis probe-based real-time PCR (real-time RT-PCR) assay
for the detection of EGFRvIII in FFPE tumor samples. This
technique relies on TaqManH hydrolysis probe-based chemistry
and achieves higher sensitivity than presently employed SYBR
green-based techniques. We demonstrated the specificity of our
method in EGFRvIII-positive and negative cell lines and then
validated our method by detecting EGFRvIII in a cohort of
glioblastoma patients. Finally, we screened a cohort of patients
with OSCC to determine the frequency of EGFRvIII mutations.
Our results suggest that the EGFRvIII mutation is rare in OSCC.
Using quantitative fluorescence immunohistochemistry and
AQUAH technology, we analyzed EGFR protein expression in
our OSCC cohort and found that exceptionally high EGFR
expression in carcinoma cells was associated with EGFRvIII
positivity.
Methods
Participants
The study cohort consisted of 102 patients with OSCC who
were treated with primary surgery (resection and neck dissection)
between 1998 and 2005 at the Foothills Medical Centre, Calgary,
Alberta, Canada. The inclusion criteria for patients were the
presentation of OSCC with no prior history or treatment for
head and neck cancer. Of the 102 patients with OSCC, 87
satisfied these inclusion criteria. Of these 87 patients who were
included in tissue microarrays (TMAs), 62 had tissue cores
suitable for quantitative immunohistochemistry. For EGFRvIII
analysis, RNA extraction from archived FFPE tumor samples was
successful in 54 out of 62 patients. Reference gene amplification
failed in 4 patients. These details are outlined in the CONSORT
diagram (Figure 1). The clinico-pathological characteristics of the
patients included in this study are represented in Table 1. In
order to address possible sample selection bias due to tumor
heterogeneity we randomly selected 22 additional FFPE tumor
blocks including the EGFRvIII-positive patient, for duplicate
EGFRvIII analysis (Table S3). Therefore, a total of 72 tumor
blocks were tested for EGFRvIII expression. Patient demographics
and clinical outcomes were collected by a combination of
comprehensive chart review and data retrieved from the Alberta
Cancer Registry.
Description of Procedures
RNA isolation and cDNA synthesis: 2–3 slices of 10 mm
thickness were sectioned from FFPE tumor blocks were and placed
in 1.5 ml centrifuge tubes. Tissues were de-paraffinized by
treatment with xylene and ethanol. Total RNA was isolated using
RecoverAll
TM Total Nucleic Acid Isolation kit (Ambion, Austin,
TX) according to manufacturer’s protocol. The U87MG cell line
was purchased from American Type Culture Collection (ATCC,
Manassas, VA); the U87MGvIII cell line was a gift from Dr. Paul
S. Mischel. Total RNA was isolated from both cell lines using
Trizol (Invitrogen, Carlsbad, CA) according to manufacturer’s
protocol. For all samples RNA concentration and purity was
determined using a Nano-Drop 2000C spectrophotometer
(Thermo Scientific, Wilmington, DE). A260/A280 nm was .1.9
for most samples. For each sample, 1 mg of RNA was used as
template in the reverse transcription reaction using qScript
TM
cDNA SuperMix (Quanta BioSciences, Gaithersburg, MD) in a
20 ml volume according to manufacturer’s protocol.
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7500 Real Time system using TaqManH probe-based chemistry
(Applied Biosystems, Carlsbad, CA). An EGFRvIII-specific gene
expression assay was designed using the File Builder 3.1 software
(Applied Biosystems, Carlsbad, CA). The following primer/probe
set was used: forward primer 59 TCTGCCCGGCGAGTC 39,
reverse primer 59 GCCGTGATCTGTCACCACATAATT 39,
FAM-labelled probe 59 TTTCTTTTCCTCCAGAGCCC 39.
Briefly, 2 ml of cDNA product was used as template in a 50 ml
PCR reaction containing 25 ml TaqManH Universal PCR Master
Mix (26), 2.5 ml EGFRvIII primer/probe mix and 20.5 ml
nuclease-free water. The following amplification protocol was
performed: 50uC for 2 minutes, 95uC for 10 minutes; followed by
40 cycles of 95uC for 15 seconds each and finally 60uC for
1 minute. Fluorescent signals were collected during the 60uC/
1 minute step. Baseline and threshold cycle number (Ct) were
determined manually. EGFRvIII PCR efficiency and linear
dynamic range was assessed by using the following dilution series:
100 ng, 10 ng, 1 ng, 0.1 ng and 0.01 ng of U87MGvIII cDNA in
triplicate. Both Beta-2-microglobulin (B2M) and GAPDH served as
reference genes.
The glioblastoma cell line U87MGvIII over-expresses EGFR-
vIII and was used as a positive control; the parental cell line,
U87MG expresses only wild-type EGFR and served as a negative
control. Water was used as a no template control for the PCR
reaction. EGFRvIII positive samples were retested to confirm the
presence of EGFRvIII and the mean Ct number was used for data
analysis. Relative expression of EGFRvIII was determined by delta
Ct method which was calculated by subtracting the average Ct
reference value from that of EGFRvIII.
Conventional RT-PCR and Sequencing: cDNA was
sequenced to verify EGFRvIII mutational status and validate the
novel EGFRvIII rt RT-PCT assay. A nested PCR strategy was
employed to maximize yield from FFPE tumor samples. Briefly,
Figure 1. CONSORT Diagram outlining patient selection criteria
and the different stages at which specific analyses were
undertaken for the OSCC study cohort.
doi:10.1371/journal.pone.0031723.g001
Table 1. Clinicopathological characteristics of OSCC patients
evaluated for EGFR protein expression and EGFRvIII frequency.
n=54
Sex (n, %)
Male 38 (70%)
Female 16 (30%)
Age (mean, sd) 61 (12.3)
Smoking History (n, %)
Never 12 (22%)
Past 12 (22%)
Current 30 (56%)
Alcohol History (n,%)
Never 6 (11%)
Moderate 19 (35%)
Heavy 15 (28%)
Former Heavy 10 (19%)
Not Stated 4 (7%)
Pathologic T Stage (n, %)
pT1 8 (15%)
pT2 19 (35%)
pT3 12 (22%)
pT4 15 (28%)
Pathologic N Stage (n, %)
pN0 28 (52%)
pN1 7 (13%)
pN2 19 (35%)
Differentiation (n, %)
Well 10 (19%)
Moderate 31 (57%)
Poor 6 (11%)
Not Stated 7 (13%)
doi:10.1371/journal.pone.0031723.t001
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volume of 50 ml containing 16High Fidelity PCR Buffer, 0.2 mM
dNTPs, 2 mM MgSO4, 20 pmol of each primer and 1 unit of
Platinum Taq High Fidelity polymerase (Invitrogen, Carlsbad,
CA). Primers are located in exon 1 and exon 10 as described
previously [29]. PCR cycling conditions were: 94uC for 2 minutes
followed by 43 cycles of 94uC/30 s, 55uC/30 s, 72uC/1 min and
a final extension step of 72uC for 10 minutes. 1 ml of first round
PCR reaction was used as template in a second round
amplification using previously reported primers and conditions
with the exception that amplification was carried out for 30 cycles
instead of 42 [30]. Nested PCR products were purified and
resuspended in 30 ml of elution buffer using the QIAquick PCR
Purification kit (Qiagen, Valencia, CA). Bi-directional sequencing
was performed using BigDyeH Terminator v3.1 Sequencing kit
(ABI) using the following primers: 59TTCGGGGAGCACC-
GATGCGAC39 (EGFR exon 1) and 59ACCAATACCTATT-
CCGTTACAC39 (EGFR exon 9). Unincorporated dye was
removed using the DyeExH 2.0 Spin Kit (Qiagen, Valencia, CA)
and capillary electrophoresis was performed on the 3130 Genetic
Analyzer (ABI).
Tissue Microarray (TMA) Construction: Formalin-fixed
paraffin–embedded (FFPE) tumor samples from patients included
in the study were retrieved for tissue microarray (TMA)
construction. Hematoxylin and eosin stained slides were reviewed
by the study pathologist (A.M) to confirm diagnosis and those
deemed to be of sufficient quality were selected and marked for
sampling and inclusion into TMAs. TMAs were assembled from
triplicate 0.6 mm cores of FFPE primary tumor samples using a
Beecher Manual Tissue Microarrayer (Beecher Instruments Inc.
Sun Prairie, WI). Five samples of normal oral cavity squamous
epithelium were also included in the TMAs as reference samples
for normal biomarker expression levels.
Quantitative Fluorescent Immunohistochemistry: We
used the HistoRx AQUAH platform and fluorescent immuno-
histochemistry [31] to quantify the expression of EGFR protein
in the tumor (epithelial) compartment of each TMA core. TMA
sections (4 mm) were deparaffinized in xylene, rinsed in ethanol,
and rehydrated. Heat induced epitope retrieval was performed
by heating slides to 121uC in a citrate-based buffer (pH 6.0)
Target Retrieval Solution (DAKO) for 6 minutes in a decloaking
chamber (Biocare Medical). TMA slides were stained for rabbit
monoclonal anti-EGFR antibody (1:1000 dilution, Epitomics)
for 60 minutes. Rabbit Envision+ kit (DAKO) was used in
conjunction with tyramide-Cy5 (Perkin-Elmer) to visualize
EGFR expression. The epithelial (tumor) compartment was
identified by staining with a guinea-pig anti-pan-cytokeratin
(PCK) antibody (ACRIS) for 60 minutes and an Alexa488
conjugated anti-guinea pig secondary antibody for 60 minutes.
Slides were scanned by HistoRx PM-2000
TM a n da n a l y z e db y
AQUAH software (version 2.2.1.7): the tumor compartment was
defined as the PCK-positive area for each TMA core. AQUAH
software calculated the EGFR expression from the average
exposure time-adjusted EGFR pixel intensity density from each
compartment. The average score from triplicate cores was
reported for the 50 patients (51 tissue blocks) for whom both
AQUA scores and real-time PCR data for EGFRvIII expression
were available.
Ethics: This study was approved by the Conjoint Health
Research Ethics Board of the University of Calgary. Written
consent for access to personal health information was waived
under Section 50 of the Alberta Health Information Act on
grounds that it was not feasible.
Results
EGFRvIII Detection in Cell lines
We detected the presence of EGFRvIII in U87MGvIII cells and
confirmed the absence of EGFRvIII in U87MG cells using our
novel real-time RT-PCR assay. These results support the
analytical specificity of our real-time RT-PCR EGFRvIII detection
method since U87MGvIII cells express both wild-type EGFR and
EGFRvIII, and the parental cell line U87MG only expresses wild-
type EGFR. Strong amplification curves were generated using
U87MGvIII cDNA as template in real-time PCR reactions
(Figure 2A). In contrast, no amplification was evident in reactions
using the U87MG cDNA template, indicating that our assay is
specific for the detection of the EGFRvIII mutation and does not
amplify wild-type EGFR.
We also confirmed the expression of EGFRvIII transcript by
direct sequencing of cDNA from both U87MG and U87MGvIII.
EGFRvIII was only detected in the U87MGvIII cell line by direct
sequencing, thus confirming the results obtained using our novel
real-time RT-PCR assay (Figure 2B). We assessed the sensitivity
and PCR efficiency of our assay by titrating a broad range of
cDNA template concentrations. EGFRvIII amplification was
achieved with template amounts as low as 10 pg. The calibration
curves (Figure 2C and 2D) demonstrate the robust linear dynamic
range and high PCR efficiency (90%) of our novel assay; these are
essential attributes for sensitive and precise real-time PCR assays.
EGFRvIII Detection in Glioblastoma FFPE Tissue
The frequency of EGFRvIII mutations in glioblastoma (,30%)
is well established in the literature [15]. Consequently, we profiled
EGFRvIII expression in tumors from a cohort of 26 glioblastoma
patients to test the EGFRvIII detection performance of our real-
time RT-PCR assay in FFPE tumor samples. For comparison, we
also attempted EGFRvIII detection using conventional RT-PCR
and direct sequencing, in the same samples. Conventional end-
point RT-PCR was successful in only 7/26 samples (4 positive and
3 negative for EGFRvIII), while target amplification failed in the
remaining 19 cases. Direct sequencing gave slightly better results;
10/26 samples produced adequate quality electropherographic
reads (5 positive and 5 negative for EGFRvIII) but electrophero-
grams were inadequate for samples from the remaining 16 tumors.
When performing our real-time RT-PCR assay on the
glioblastoma samples, we used B2M as the reference gene. B2M
was amplified successfully in all samples (26/26), while EGFRvIII
was amplified in 10/26 samples. The detection of EGFRvIII by
conventional RT-PCR and our novel real-time RT-PCR analysis
were fully concordant; all samples that were EGFRvIII-positive by
conventional RT-PCR were also EGFRvIII-positive according to
our real-time RT-PCR analysis. Additionally, of the three tumor
samples that were EGFRvIII-negative (expressing only wtEGFR)
according to RT-PCR, two were re-classified as EGFRvIII-positive
by our real-time RT-PCR assay; these tumor samples had high
EGFRvIII Ct values and very high DCt values (Table S1).
The detection of EGFRvIII by our novel real-time RT-PCR
method was fully concordant with the detection of EGFRvIII by
direct sequencing in glioblastoma FFPE samples; all samples that
tested positive for EGFRvIII by direct sequencing were also
EGFRvIII-positive according to our novel real-time RT-PCR
assay. Of the five samples that were EGFRvIII-negative by direct
sequencing, two were re-classified as EGFRvIII-positive by our
novel real-time RT-PCR method. These two samples only
amplified a wild-type EGFR product by conventional RT-PCR
but had high EGFRvIII Ct and DCt values when analyzed by our
novel real-time RT-PCR. These results demonstrate the low
EGFRvIII Expression in Oral Cancer
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sequencing methods when applied to FFPE tissue samples.
Compromised RNA quality and fragmentation limits the size of
amplicons that can be generated from FFPE tissue, thus rendering
them unsuitable for conventional PCR and direct sequencing
applications. Another possibility might be the low abundance of
the EGFRvIII transcript in these samples that may be attributed to
the tumor heterogeneity of glioblastomas.
EGFRvIII Detection in OSCC FFPE Tissue
We evaluated tumor samples from 54 OSCC patients for the
presence of EGFRvIII using our novel real-time RT-PCR assay.
Figure 2. Specific detection of EGFRvIII mRNA by real-time RT-PCR. A. Real-time amplification plot of EGFRvIII transcript as detected in the
U87MGvIII cell-line. U87MGvIII cells were used as a positive control, U87MG cells were used as negative control: water was used for no template
control. B. Direct sequencing of U87MG and U87MGvIII cDNA confirms the presence of EGFRvIII transcript in U87MGvIII cells only. The broken arrow
indicates the EGFRvIII-specific exon 1 and exon 8 junction. C. Linear dynamic range of the EGFRvIII real-time RT-PCR assay (100, 10, 1, 0.1 and 0.01 ng
cDNA). D. EGFRvIII real-time RT-PCR assay amplification efficiency.
doi:10.1371/journal.pone.0031723.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31723Figure 3. Conventional RT-PCR and direct cDNA sequencing confirm the presence of EGFRvIII in glioblastoma FFPE tissue. A.
Conventional RT-PCR failed for GBM 11, GBM 23 and GBM 19. GBM 9 is positive for EGFRvIII. EGFRvIII positive control: U87MGvIII (384 bp), negative
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amplification of the reference genes (B2M and GAPDH) or having
Ct values greater than 38 for one or both of these reference genes.
All other samples successfully amplified both reference genes. Our
real time PCR assay revealed that only one patient (1/50) was
positive for EGFRvIII mRNA expression (Figure 3C and Table
S2). Retesting of this sample confirmed EGFRvIII positivity. In
addition, both direct cDNA sequencing and conventional RT-
PCR were performed on this sample, however both methods failed
outright. This failure may be attributed to formalin fixation-
induced degradation and modification of DNA/RNA and further
highlights the limitations of conventional methods when using
FFPE tissue.
We also measured total EGFR protein levels for all samples by
quantitative fluorescent immunohistochemistry using the HistoRx
AQUAH platform [31] (Figure 4A). EGFR AQUA scores,
representing the concentration of EGFR protein, showed a range
of expression from 426 to 1696 in normal oral cavity squamous
epithelium with a median score of 1151 and a standard deviation
of 6406 (Figure 4B, blue lines). We used the median EGFR
AQUA score plus one standard deviation (AQUA=1557) as our
definition for EGFR over-expression. Using this definition, we
found that tumors from 22 of 50 patients over-expressed EGFR.
Comparison of EGFR AQUA scores with EGFRvIII expression
showed that the tumor sample with the highest EGFR AQUA
score was the EGFRvIII-positive case identified by our real-time
RT-PCR assay (Figure 4A, bottom panel; Figure 4B red line;
Table S2). In order to address tumor heterogeneity, an additional
FFPE tumour block was randomly selected from 22 patients in the
cohort and was tested for EGFRvIII expression (see methods
section for details; Table S3). The additional samples included a
tumor block from the patient that had tested positive for EGFRvIII.
EGFRvIII transcript was not present in any of these additional
tumor samples (Table S3). Furthermore, AQUAnalysisH of the
EGFRvIII-negative sample obtained from the single EGFRvIII-
positive patient showed this sample to have significantly lower
wild-type EGFR protein expression (Table S2). Taken together,
these results suggest that EGFRvIII expression in OSCC is a rare
event (2%) and most likely to be present in tumors which express
very high levels of EGFR protein.
Discussion
We have developed a highly sensitive and specific real-time RT-
PCR assay for EGFRvIII detection. We validated our assay in a
cohort of glioblastoma patients and compared its efficiency to
conventional PCR and direct sequencing. Furthermore, in light of
the conflicting reports regarding the frequency of EGFRvIII in
HNSCC [21,22,23,25], we investigated the frequency of EGFRvIII
in OSCC, the most prevalent form of HNSCC, using our novel
technique. Despite the highly sensitive nature of our assay, we only
detected a single EGFRvIII-positive patient in our OSCC cohort of
50 patients. This discrepancy between our novel real-time RT-
PCR assay results and the reported frequency of EGFRvIII in
HNSCC may be due to differing EGFRvIII mutation frequencies
in specific HNSCC subsites or selection bias inherent in early
phase clinical trials. Patient eligibility for such trials was based on
recurrent or metastatic disease status or failure of first-line therapy
[23]. Since EGFRvIII-positive tumors are expected to be less
responsive to conventional therapies than EGFRvIII-negative
tumors, it would be expected that EGFRvIII-positive tumors would
be over-represented in these cohorts. The cohort in the current
study included patients with no prior treatment for HNSCC and
may more accurately reflect the frequency of EGFRvIII in this
disease site. The low EGFRvIII frequency reported in another
unselected HNSCC cohort [21] supports this assertion.
Since EGFR over-expression and amplification of the EGFR
locus has been linked to the presence of EGFRvIII [9], we used
quantitative immunohistochemistry and AQUAH technology to
measure EGFR expression in TMAs constructed from our patient
tumor samples. The single OSCC patient that tested positive for
EGFRvIII also exhibited the highest expression of EGFR protein.
This increased staining may be attributed to the presence of both
wild-type and mutant forms of EGFR, since our EGFR antibody
detects both wild-type EGFR and EGFRvIII. Also, the absence of
EGFRvIII in an additional tumor sample from the same patient,
and expressing significantly lower levels of EGFR, corroborates
reports suggesting that EGFR over-expression is linked to the
presence of EGFRvIII. The apparent mosaic pattern of EGFRvIII
expression in the EGFRvIII-positive patient also confirms the
heterogeneity of OSCC similar to malignant glioblastomas, where
the proportion of EGFRvIII-expressing cells has been shown to
range from 37% to 86% in EGFRvIII-positive tumor samples [32].
The cancer-specific EGFRvIII deletion mutant is the focus of
investigation in a variety of cancers. In vitro and in vivo studies attest
to the increased tumorogenicity of EGFRvIII expressing cells [22],
thus making it a prime target for novel therapies. However, the
implementation of these therapies is contingent on the accurate
and sensitive detection of EGFRvIII in tumor samples. A variety of
methods are available for the detection of EGFRvIII in clinical
specimens. Fresh frozen tissue samples are amenable to conven-
tional RT-PCR and direct sequencing-based detection methods
but these techniques are unreliable in FFPE samples. RNA
isolated from paraffin-embedded tissue is often highly degraded
and compromised by cross-linking and modifications introduced
during the fixation process. This can prove challenging for
downstream applications such as PCR where high nucleic acid
integrity is essential. Immunohistochemical detection of EGFRvIII
protein can achieve high sensitivity and specificity, attributed to
the presence of a unique glycine residue in EGFRvIII. However,
the widespread clinical use of EGRFvIII immunohistochemistry is
restricted by patents and availability of antibodies. Several real-
time PCR-based techniques have also been described in the
literature and their utility in FFPE tumor samples has been
successfully demonstrated. A majority of these techniques use dye-
based chemistries and are less specific than probe-based assays,
rendering them more prone to the detection of false positives. Also,
the sensitivity of some of these real-time PCR-based methods may
be inadequate for detecting trace amounts of EGFRvIII mRNA
that might be present in early stage tumor samples. Our novel rt
RT-PCT assay is less prone to the detection of false positives due
to its specificity for EGFRvIII. It is optimized for the detection of
EGFRvIII in FFPE tumor samples because of its sensitivity towards
small amplicon sizes and its inability to detect the presence of wild-
type EGFR.
This is the first report describing the frequency of EGFRvIII
specifically in OSCC. Despite advances in therapy, long-term
survival in OSCC patients remains poor. The overall survival rate,
worldwide, from oral cancer is generally less than 50% and has
remained unchanged for more than three decades [33,34].
control: U87MG (1184 bp) and no template control (NTC): water. B. Sequencing of GBM 9 cDNA confirms the presence of EGFRvIII. C. Real-time
amplification plot showing EGFRvIII-positive OSCC patient (13A) and the positive control (U87MGvIII).
doi:10.1371/journal.pone.0031723.g003
EGFRvIII Expression in Oral Cancer
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31723Recently, there has been a concerted effort towards the
development of EGFR-targeted therapies in OSCC. Also, several
groups have advocated the use of EGFRvIII-specific therapies in
HNSCC patients. Our results suggest that EGFRvIII-specific
therapies may not be ideally suited as first-line treatment in OSCC
due to the low occurrence of EGFRvIII at this subsite. However,
EGFRvIII targeting might be a valuable addition to therapeutic
regimens in recurrent/metastatic OSCC where EGFRvIII might
Figure 4. Immunofluorescent staining and quantitative analysis of EGFR protein expression in OSCC samples using the HistoRx
AQUAH platform. A. Representative examples of normal oral cavity squamous epithelium in the top panel, a low expressing tumor from an
EGFRvIII-negative patient in the top-mid panel, and the EGFRvIII negative and EGFRvIIIitive samples from patient 13 in the bottom two panels. DAPI
(blue)=nuclei, pan-cytokeratin (green)=epithelial/tumor cells, and EGFR (red). B. Histogram distribution of the EGFR AQUA scores for the entire OSCC
patient cohort. The red and green lines indicate the EGFR scores for patient 13 who had both an EGFRvIII-positive (red, Sample ID 13A) and EGFRvIII-
negative (green, Sample ID 13B) tumor sample. The solid blue line indicates the median EGFR AQUA score for normal oral cavity squamous
epithelium, surrounded by the hashed blue lines representing one standard deviation above and below the median.
doi:10.1371/journal.pone.0031723.g004
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refractory to EGFR-targeted therapy [22], this may explain the
poor success of EGFR targeting in clinical trials involving HNSCC
patients [35,36,37]. Therefore, testing for EGFRvIII frequency
could provide greater benefits in patients with advanced disease
and treatment failures.
Our AQUAnalysisH suggests that EGFR is over-expressed in
44% of OSCC. This is in contrast with reports where EGFR over-
expression has been described in ,100% of OSCC [38]. The
discrepancy in the reported frequency of EGFR protein over-
expression in OSCC could be attributed to our more stringent
definition of EGFR over-expression; we used quantitative
fluorescent immunohistochemistry for the assessment of EGFR
expression in normal and malignant tissue and defined EGFR
over-expression relative to EGFR expression in normal tissue.
Additionally, the automated, observer-independent nature of
AQUAH yields highly reproducible protein expression data on a
continuous scale, providing better resolution between patients than
conventional semi-quantitative IHC.
We conclude that highly specific and sensitive methods, such as
the real-time RT-PCR assay and quantitative fluorescent immu-
nohistochemistry described in this research, are essential for
accurate assessment of EGFR expression and EGFR mutations,
and will facilitate the selection of optimal tailored therapies for
OSCC patients. Also, improved screening methods for EGFR and
other cancer-specific abnormalities, should be incorporated into
routine clinical diagnostic testing to pave the way for early
diagnosis and improved survival in OSCC. In keeping with this
goal, several prominent cancer centers are already using the
routine analysis of biopsies to identify gene mutations and triage
cancer patients for targeted therapies [39].
Limitations
We studied a relatively small retrospective cohort of OSCC
patients. Translation of our findings into changes in clinical
practice would require confirmation in a prospective clinical
setting.
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